Prof. Martin Reck (German Center for Lung Research, Germany) cited recent data from landmark trials to promote immunotherapy combined with other treatment options. “We have suggestions of multiple interactions and potential synergies,” said Prof. Reck at a mini-symposium on the Future of IO. These include immunotherapy plus chemotherapy, targeted therapies, and anti-VEGF therapy. In addition, a broad range of immuno-oncology agents can be combined to boost efficacy.
In squamous cell NSCLC, the practice-changing KEYNOTE-407 trial showed significantly increased overall survival (OS) with immunotherapy plus chemotherapy. The median OS was 15.9 months in the pembrolizumab group vs 11.3 months in the chemotherapy-alone group (HR 0.64; P=0.0008) .
According to Prof. Reck, efficacy was independent from PD-L1 status and there were no increases in immune-related adverse events (AEs) despite differences in the trial populations. OS outcomes were similar in phase 3 randomis...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Next generation immunotherapy in non-small-cell lung cancer Next Article
Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer »
Table of Contents: WCLC 2018
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.